Every 424B that TriSalus Life Sciences, Inc. (TLSI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow TLSI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TLSI filings page.
TriSalus Life Sciences is offering 9,756,100 shares of Common Stock at a public offering price of $4.10 per share, as set forth in the prospectus supplement dated February 19, 2026. The offering includes a 30-day underwriter option to purchase up to 1,463,415 additional shares.
The cover page shows aggregate public offering proceeds of $40,000,010, underwriting discounts of $2,400,000, and estimated proceeds to the company before expenses of $37,600,010. The prospectus supplement states estimated net proceeds of approximately $37.0 million (or approximately $42.64 million if the over-allotment is exercised in full) to be used for general corporate purposes.
TriSalus Life Sciences filed a prospectus supplement to offer 9,756,100 shares of Common Stock at a public offering price of $4.10 per share, with a 30-day underwriter option for 1,463,415 additional shares. Net proceeds are estimated at approximately $37.0M (or $42.64M if the option is fully exercised) to be used for general corporate purposes.
The prospectus states pro forma shares outstanding of 59,811,590 after the offering (or 61,275,005 if the over-allotment is exercised). Preliminary unaudited results disclose $13.2M in fourth-quarter 2025 revenue, full-year 2025 revenue of $45.2M, and cash and cash equivalents of approximately $20.4M as of December 31, 2025.
TriSalus Life Sciences, Inc. is offering shares of its common stock pursuant to a preliminary prospectus supplement dated February 19, 2026. The prospectus supplement supplements a shelf registration and describes the terms and mechanics of a primary offering of Common Stock listed on Nasdaq as "TLSI."
The filing discloses preliminary unaudited financial context: estimated Q4 2025 revenue of $13.2 million, full-year 2025 revenue of $45.2 million, and approximately $20.4 million of cash and cash equivalents as of December 31, 2025. The company states net proceeds will be used for general corporate purposes and that underwriting details, offering price and number of shares are set forth in the prospectus supplement (subject to completion).